Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arecor Therapeutics PLC ( (GB:AREC) ) has issued an announcement.
Arecor Therapeutics plc reported its interim results for the first half of 2025, highlighting significant progress in its diabetes and obesity drug development portfolios. The company received positive FDA feedback for its AT278 insulin product and signed a co-development agreement with Sequel Med Tech for Phase 2 activities, extending its cash runway to 2027. The company also made strides in its oral peptide delivery platform, aiming to improve patient accessibility and outcomes in the growing peptide therapeutics market. Financially, Arecor maintained steady revenue, reduced losses, and secured a royalty financing agreement with Ligand Pharmaceuticals, bolstering its financial position.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics PLC’s stock is buoyed by strong technical indicators and positive corporate events, despite financial challenges typical of early-stage biotech companies. The technical analysis and corporate events significantly contribute to the overall score, highlighting market confidence and strategic growth initiatives.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a clinical stage biopharmaceutical company based in Cambridge, UK, focused on drug development and delivery for diabetes and other cardiometabolic diseases. The company utilizes its proprietary Arestat® technology platform to develop a portfolio of proprietary products and collaborates with leading pharmaceutical and biotechnology companies to enhance therapeutic products. Its lead product, AT278, is an ultra-concentrated ultra-rapid acting insulin, and the company is also working on a novel oral delivery platform for peptides targeting the obesity and diabetes markets.
Average Trading Volume: 57,175
Technical Sentiment Signal: Hold
Current Market Cap: £27.37M
For a thorough assessment of AREC stock, go to TipRanks’ Stock Analysis page.